Orthofix Medical Inc. (NASDAQ:OFIX) Chief Legal Officer Jorge Andres Cedron completed the sale of a total of 2,775 shares of the company’s common stock across two days in early March 2026, generating proceeds of $35,341.
On March 4, Cedron sold 1,405 shares in multiple trades at prices that ranged between $12.80 and $13.03, yielding a weighted average price of $12.9163 for that day’s activity. After those sales, his direct holdings stood at 64,119 shares, a figure that includes 53,902 restricted stock units (RSUs).
The following day, March 5, Cedron disposed of an additional 1,370 shares in several transactions at prices between $12.48 and $12.72, producing a weighted average price of $12.5508 for that tranche. After the March 5 transactions, his direct ownership totaled 62,749 shares, again reflecting 53,902 restricted stock units among those holdings.
The company has said the sales were carried out to satisfy tax withholding obligations associated with the settlement of restricted stock units, in accordance with the Compensation and Talent Development Committee of Orthofix Medical’s Board of Directors.
At the time of the reported transactions, Orthofix shares were trading at $12.63. The stock has declined 17% year-to-date and 25% over the prior 12 months, according to the market snapshot cited alongside the filings.
Investment analysis included in the company commentary indicates that the shares appear undervalued relative to their Fair Value, with expectations that Orthofix will return to profitability during the current year after recording a loss of $2.33 per share over the last twelve months. Those valuation notes are accompanied by a reference to a Pro Research Report available for this and more than 1,400 other U.S. equities.
Separately, Orthofix’s fourth-quarter 2025 results showed an earnings-per-share loss of $0.06, which was a smaller loss than analysts had modeled and therefore represented a positive surprise versus expectations of a $0.22 per-share loss. The company reported revenue of $219.9 million for the quarter, modestly above the projected $218.57 million figure. The earnings release and revenue performance were highlighted as recent developments accompanying the insider transactions.
The filings and company commentary provide a factual record of the insider sales, their stated purpose, current ownership levels for the officer involved, recent quarterly operating results, and a valuation viewpoint cited alongside the market data. The materials do not present additional commentary from company management beyond the tax withholding rationale for the share sales.